SLC5A2 and type 2 diabetes mellitus: While our results suggest statistical evidence of a lower percentage of ethnic minorities and people from more deprived areas in England being prescribed SGLT2 inhibitors compared with people of White ethnicity, these differences were not substantial and unlikely to represent major disparities in T2DM care.